Enlivex Therapeutics Reports Positive Phase I/II Trial Data
Ticker: ENLV · Form: 6-K · Filed: Jun 17, 2024 · CIK: 1596812
Sentiment: bullish
Topics: clinical-trial-data, biotech, covid-19
Related Tickers: ENLV
TL;DR
Enlivex $ENLV drops good Phase I/II COVID-19 trial data, looks promising.
AI Summary
On June 17, 2024, Enlivex Therapeutics Ltd. announced positive interim data from a Phase I/II investigator-initiated clinical trial for its drug candidate, Allocetra. The trial evaluated Allocetra in patients with severe COVID-19.
Why It Matters
Positive trial data could advance Enlivex's drug candidate towards further clinical development and potential market approval, impacting treatment options for severe COVID-19.
Risk Assessment
Risk Level: medium — Clinical trial results, especially interim data, carry inherent uncertainty and are subject to further validation and regulatory review.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra (drug_candidate) — Drug being evaluated
- June 17, 2024 (date) — Date of announcement
- Phase I/II (clinical_trial_phase) — Stage of the clinical trial
- COVID-19 (disease) — Condition being treated
FAQ
What specific positive interim data was announced for the Phase I/II trial?
The filing states that positive interim data was announced, but the specific details of this data are not included in the provided text. The full press release would contain these specifics.
What is the name of the drug candidate being evaluated in the trial?
The drug candidate being evaluated is named Allocetra.
What type of clinical trial is this, and for what condition?
This is a Phase I/II investigator-initiated clinical trial evaluating Allocetra in patients with severe COVID-19.
When was this announcement made?
The announcement was made on June 17, 2024.
What is the company's primary business?
Enlivex Therapeutics Ltd. is involved in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification code 2834.
Filing Stats: 222 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-06-17 08:03:18
Filing Documents
- ea0207745-6k_enlivex.htm (6-K) — 9KB
- ea020774501ex99-1_enlivex.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- ex99-1_002.jpg (GRAPHIC) — 12KB
- 0001213900-24-053148.txt ( ) — 51KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: June 17, 2024 2